Patent Thicket Remedies
Yesterday, the Initiative for Medicines, Access, and Knowledge I-MAK took an important step by proposing six policy solutions to address patent thickets that block generic and biosimilar drug competition.
New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”
Patent Thickets Constrain US Biosimilars Market
Biosimilars represent a significant cost-savings opportunity in the United States because they can introduce competition for some of the most expensive and widely used prescription drugs on the market: originator biologics. Several market and regulatory barriers have slowed biosimilar market entry and uptake in the United States.
- Patent Thicket Remedies
- Don’t Mix US Tax Administration Policy with the Israel-Hamas Conflict
- The Economics of “Delinking” PBM Compensation
- The Supreme Court Should Leave the Tax Code Alone
- Implications of Cannabis Legalization for the US Federal Budget
- Amicus Brief in Moore v. United States
- Biosimilars – Keys to Success in the Pharmacy Benefit
- New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
- MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
- Unintended Consequences of Limiting PBMs
